Durable clinical benefit and progression-free survival in patients with PD-L1 ≥50% NSCLC receiving pembrolizumab: Impact of nutritional and inflammatory markers
{{output}}
Background: Immune checkpoint inhibitors (ICIs) are effective in advanced non-small cell lung cancer (NSCLC) with PD-L1 expression ≥50 %; however, responses remain heterogeneous. We investigated the predictive value of nutrition... ...
